Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5745 and Bevacizumab in Recurrent Glioblastoma
NCT03631836Phase 1Unknown
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Jan 2019
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of andecaliximab in glioblastoma (GBM), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Dose Limiting Toxicity at 36 months. Status: unknown.
02
Drugs
andecaliximab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03631836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631836.